New York State Common Retirement Fund Cyma Bay Therapeutics, Inc. Transaction History

New York State Common Retirement Fund

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$12.63 - $24.47 $386,970 - $749,736	30,639 Added 47.57%	95,043 $2.25 Million
Q3 2023 Nov 07, 2023	BUY	$10.86 - $17.62 $199,617 - $323,873	18,381 Added 39.94%	64,404 $960,000
Q2 2023 Aug 07, 2023	BUY	$7.47 - $10.95 $343,791 - $503,951	46,023 New	46,023 $504,000
Q2 2022 Aug 04, 2022	SELL	$1.72 - $3.39 $49,873 - $98,296	-28,996 Reduced 98.03%	584 $2,000
Q4 2021 Feb 02, 2022	SELL	$3.23 - $4.6 $390 - $556	-121 Reduced 0.41%	29,580 $100,000
Q3 2021 Nov 02, 2021	SELL	$3.47 - $4.42 $87,666 - $111,666	-25,264 Reduced 45.96%	29,701 $108,000
Q2 2021 Aug 02, 2021	BUY	$3.94 - $4.92 $2,226 - $2,779	565 Added 1.04%	54,965 $240,000
Q3 2019 Nov 07, 2019	SELL	$5.12 - $7.21 $82,432 - $116,081	-16,100 Reduced 22.84%	54,400 $279,000
Q2 2019 Aug 09, 2019	BUY	$6.05 - $13.66 $98,010 - $221,292	16,200 Added 29.83%	70,500 $505,000
Q4 2018 Feb 08, 2019	SELL	$6.54 - $11.74 $73,248 - $131,488	-11,200 Reduced 17.1%	54,300 $427,000
Q2 2018 Aug 10, 2018	BUY	$10.66 - $14.38 $698,230 - $941,890	65,500 New	65,500 $879,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.